Cross-resistance to cefiderocol and ceftazidime–avibactam in KPC β-lactamase mutants and the inoculum effect

Impact of anticancer chemotherapy on the extension of beta-lactamase spectrum: an example with KPC-type carbapenemase activity towards ceftazidime-avibactam

(2020) Claire Amaris Hobson et al.   Scientific Reports

KPC beta-lactamases are permissive to insertions and deletions conferring substrate spectrum modifications and resistance to ceftazidime-avibactam

(2020) Claire Amaris Hobson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial

(2020) Richard G Wunderink et al.   LANCET INFECTIOUS DISEASES

Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014)

(2020) Naoki Kohira et al.   Journal of Global Antimicrobial Resistance

Emergence of ceftazidime/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo

(2019) Stephan Göttig et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections

(2018) Ryan K. Shields et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Beta-lactamase database (BLDB) – structure and function

(2017) Thierry Naas et al.   JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY

In VitroSelection of Ceftazidime-Avibactam Resistance in Enterobacteriaceae with KPC-3 Carbapenemase

(2015) David M. Livermore et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY